Resumen
Therapeutic vaccines represent an attractive strategy for cancer patients but have not yet achieved significant efficacy. Many strategies are currently being explored to improve their efficacy and, notably, different types of adjuvants are under development. Nanoparticle systems are promising adjuvants as they act as carriers for antigens to target antigen-presenting cells in lymph nodes. Among them, melanin-based nanoparticles are particularly interesting since they efficiently carry antigens into draining lymphoid tissues and display immunomodulatory properties. In addition, melanin-based nanoparticles can also play an active role in triggering anti-cancer responses in the context of photothermal therapy. This review summarizes the promising results of the melanin-based cancer vaccines recently reported in preclinical models.